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B-cell precursor acute lymphoblastic leukemias (pB-ALLs)
are the most frequent type of malignancies of the childhood,
and also affect an important proportion of adult patients. In
spite of their apparent homogeneity, pB-ALL comprises a
group of diseases very different both clinically and
pathologically, and with very diverse outcomes as a
consequence of their biology, and underlying molecular
alterations. Their understanding (as a prerequisite for their
cure) will require a sustained multidisciplinary effort from
professionals coming from many different ﬁelds. Among all
the available tools for pB-ALL research, the use of animal
models stands, as of today, as the most powerful approach,
not only for the understanding of the origin and evolution of
the disease, but also for the development of new therapies. In
this review we go over the most relevant (historically,
technically or biologically) genetically engineered mouse
models (GEMMs) of human pB-ALLs that have been
generated over the last 20 years. Our ﬁnal aim is to outline
the most relevant guidelines that should be followed to
generate an “ideal” animal model that could become a
standard for the study of human pB-ALL leukemia, and which
could be shared among research groups and drug
development companies in order to unify criteria for studies
like drug testing, analysis of the inﬂuence of environmental
risk factors, or studying the role of both low-penetrance
mutations and cancer susceptibility alterations.
pB-ALL is a clonal malignant disease clinically characterized
by a massive accumulation of immature CD10C, CD19C lym-
phocytes that interferes with normal haematopoietic develop-
ment. B-lineage leukemias are the most frequent ones within the
lymphoid leukemia groups in both children (where >80% ALLs
are pB-ALLs) and adults (>75%).1 The origin of leukemia in
humans is often impossible to determine, due to the advanced
tumoral stages in the children when they enter the clinic. Our
knowledge about the etiology of leukemia is consequently mainly
derived from animal models that recapitulate human disease. In
spite of many attempts over the last 2 decades, animal models
faithfully recapitulating all the aspects of human pB-ALL are still
an essential unmet need. These models should allow us to dissect
the processes that lead to human pB-ALL, and therefore, should
also shed light on the unsolved questions about the role of envi-
ronmental factors in pB-ALL development (Fig. 1). But the ques-
tion therefore is: can we mimic/reproduce human pB-ALL
disease in the mouse? The final objective should be to be able of
mimicking in the mouse the entire molecular, cellular, histologi-
cal and organic characteristics of human pB-ALL, including its
initiation, progression, evolution, response to therapy and even-
tual cure or relapse. The models should present similar histologi-
cal features to those seen in human cancer, should progress
through the same stages, present the same systemic effects that
leukemia induces it the human patients, should involve the same
genetic pathways implicated in human tumor initiation and pro-
gression, and must have the same response to current therapeutic
approaches. However, all pB-ALL models generated so far have
diverse shortcomings in their capacity of mimicking the human
disease.
pB-ALL non-murine versus murine models
The haematopoietic system has been well-characterized in
many common experimental models, and this is the case of 2 of
the most relevant ones, zebrafish (Danio rerio) and Drosophila.2,3
Drosophila is, in itself, a tremendously powerful system for the
study of genetic and molecular interactions among key player
genes in leukemia but its possibilities of mimicking full human
leukemia are very limited, particularly since true malignancies do
not really develop in the fly. The zebrafish also offers important
advantages for the investigation of developmental hematopoiesis
and of the molecular mechanisms of leukemogenesis.4 In general,
zebrafish models have been very useful for the identification of
secondary hits partners in forward genetics mutagenesis screens.
However, with the advent of genomic technologies and the
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capacity of sequencing the full genome of cancer patients, the dis-
covery of the mutations participating in the disease at all its
stages, directly in the human, has become much easier. In sum-
mary, even taking into account the many similarities of zebrafish
haematopoietic system with that from mammals, still the differ-
ences are relevant enough so as to prevent us from considering
this model as a suitable model for reproducing all the aspects of
human disease. As a way of an example, one of the main prob-
lems is the fact that zebrafish has a duplicated genome. Since
chromosomal gains and losses are very important events in leuke-
mic development, this biological fact makes zebrafish less ade-
quate for ALL modeling.
Xenotransplants/retroviral transduction models vs. GEMMs
Until recently, the study of the origin of leukemia has been
primarily addressed by transplantation of purified subpopula-
tions (putative leukemia-initiating cells, LICs) of human pB-ALL
cells into immunodeficient mice. From a leukemia developmen-
tal point of view, this technological approach has been extremely
useful in demonstrating the hierarchical structure of many
human pB-ALL types.5-10 However, these models are very diffi-
cult to standardize between laboratories, thus precluding the
good reproducibility of the results.11 Other disadvantages, of
especial relevance for the study of the role of the stroma in
tumoral evolution, are that recipient mice should be irradiated
with gamma radiation before the injection of transduced cells
(2 to 9 Gy), and also that the human leukemia develops into oth-
erwise normal/immunocompetent human children. This meth-
odological need also clearly precludes the use of these approaches
for the study of the effects of several environmental factors (nota-
bly electromagnetic fields) in childhood pB-ALL.
Given the mentioned limitations of the xenografts of human
samples to understand leukemia biology/etiology, other possible
approach that has been employed for the modeling of pB-ALL
is the introduction (usually by viral transduction) of the human
translocation genes in either human or mouse blood progenitors
(or, in a less optimal setup, cell lines) and then to re-inject
them into mice and observe their development. This approach
has been instrumental for defining many biological properties
of oncogenes, and for the development of gene therapy
approaches. Nevertheless, all these virus-based models present
limitations of inter-laboratory reproducibility and homogeneity,
mainly due to 3 reasons: it is an ex vivo based method that does
not mimic human cancer origin, the viral integration is poten-
tially mutagenic by itself, and the recipient mice should also be
irradiated with gamma radiation before the injection of trans-
duced cells. Therefore, although very useful for basic research,
their potential for understanding the etiology of human pB-
ALL leukemias and for large-scale inter-laboratory approaches is
limited.
Figure 1. Desired characteristics for an ideal pB-ALL GEMM. (A) WT mice do not have any tendency to spontaneously develop pB-ALL. (B) When exposed
to environmental agents (to test for their capacity of inducing pB-ALL), WT mice do not develop human-like pB-ALLs (except for ionizing radiations,
whose molecular mechanisms of leukemogenicity differ from spontaneous human pB-ALLs). (C) Conventional GEMMs generated so far without taking
into account the nature of the human pB-ALL cell-of-origin fail to generate human-like pB-ALL, although they consistently give rise to different types of
haematopoietic malignancies. (D) One way for the successful generation of GEMMs developing human-like pB-ALL would be to take into account the
nature of the leukemic cell-of-origin in humans (most likely in the bone marrow), and to consider that leukemias arise from a few cells in the context of a
normal tissue. These mice might develop human-like pB-ALL, and the incidence, onset or pathogenicity of the disease should increase in the presence
of any real leukemia-inducing environmental agent.
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Genetically engineered mouse models of pB-ALLs
Therefore, in order to accurately reproduce all the aspects
intervening in pB-ALL development, it is necessary to perform
experiments in an in vivo setting in which the neoplasm emerges
in the appropriate microenvironment. The complexity of model-
ing cancer in mice has increased to the extent that nowadays one
can induce, study and manipulate the leukemic process in a man-
ner impossible to perform in human patients or with human-
derived samples. However, from a historical perspective, the crea-
tion of every single GEMM has been clearly influenced at each
time point by the existing knowledge and level of characterization
of human pB-ALL through the appearance of new technological
approaches (PCR, advanced flow cytometry, fluorescence in situ
hybridization, etc.).
The number and type of genetic alterations associated with
leukemia is varied but limited. Leaving aside chromosomal aneu-
ploidies, these alterations can be roughly grouped into gain-of-
function mutations, usually resulting from chromosomal translo-
cations and assumed to be the first leukemogenic hits, and loss-
of-function mutations that are typically considered second hits
(but not always). In the next sections we will revise the most rele-
vant (historically, technically or biologically) mouse models of
precursor B-ALLs, and we will not consider other B cell malig-
nancies.12,13 For each of the most relevant pB-ALL-associated
genetic alterations we will first describe constitutive one-hit mod-
els, 2-hit models, followed by conditional and/or inducible mod-
els (indistinctly one or 2-hit models).
BCR-ABLC GEMMs
Since the discovery that chimeric fusion proteins are tightly
associated with specific leukemic types in human patients, gain-
of-function mouse models started to be generated trying to repro-
duce human disease by ectopically expressing the oncogenic pro-
teins in the mouse. At the beginning, these models were
generated by classical transgenesis. In 1990, Heisterkamp et al.14
demonstrated the oncogenic capacity of the BCR-ABLp190
fusion protein by expressing it under the control of the methalo-
thionein promoter in the mouse, and showing that the resulting
mice died of acute leukemia (myeloid or lymphoid) in a few
weeks. With this model it was also already noted that, even when
using a transgene expressed in many different cell types, the phe-
notype of the disease was specifically restricted to the haemato-
poietic system, as dictated by the oncogene.15 Although some
reports have described differences in the phenotype resulting
from the transgenic expression of the different BCR-ABL
forms,16 given the fact that all the BCR-ABL oncogenes, in spite
of their differences, are kinases, there is a significant extent of
overlapping aberrant phenotypes associated to their overexpres-
sion in different transgenic settings. For example, BCR-ABLp210
expressed under the control of the mouse bcr locus is embryonic
lethal,17 while under the methallothionein promoter, it causes T-
cell leukemia.18 The bcr-ABLp190 oncogene made by homolo-
gous recombination into the mouse bcr locus produced acute leu-
kemias in the chimeras of a B-cell precursor immunophenotype,
mimicking the human pathology.19 Also using this model, it was
shown that the endogenous bcr locus was not required for the
disease to develop. However, the chimeras did not transmit and
the constitutive expression of BCR-ABLp190 in all the cells of F1
mice led to embryonic lethality, similarly as previously men-
tioned for the p210 form.
In this context, the additional introduction of second hits
(either gains or losses of function) selected on basis of their
known involvement in human pB-ALL or in normal B cell devel-
opment, has allowed confirming, in many cases, the molecular
mechanisms of leukemic evolution. For example, one of the most
common secondary alterations in human BCR-ABLC pB-ALLs is
the deletion of the IKZF1 (IKAROS) gene.20-22 Crossing trans-
genic BCR-ABL mice14 with mice carrying an hypomorphic
Ikzf1 allele23 showed that impaired Ikaros function indeed accel-
erates leukemic progression and tumor onset by circumventing
the need to accumulate other additional genetic hits that might
cooperate with the BCR-ABL oncogene in pB-ALL.24
A particular experimental approach standing in between
GEMMs and viral transduction involves the use of bone marrow
cells from genetically modified mice as a target for viral transduc-
tion. Generally, the target cells used are derived from a mouse
carrying the “second hit” (usually a loss-of-function allele, versus
WT control cells) and they are transduced with the “first hit”
oncogene. This approach has been used, for example, to study
the role of the p19ARF locus in the phenotype of BCR-ABLC pB-
ALLs.25,26 Retroviral transduction of BCR-ABLp185 into
Arf¡/¡ mouse bone marrow cells rapidly generates polyclonal
populations of continuously self-renewing pre-B cells, virtually
all of which have leukemic potential.26 Also, in the presence of
WT p19ARF, the only cells that can be transformed by BCR-ABL
expression are haematopoietic stem cells (HSCs), while in an
Arf¡/- background, also common lymphoid progenitors (CLPs)
and early B lymphocyte precursors can generate leukemic stem
cells.25 This mouse model was afterwards used to demonstrate
that NFAT inhibition with cyclosporine-A enabled leukemia cell
eradication by the BCR-ABL inhibitor dasatinib, and signifi-
cantly improved mice survival.27 Similar experimental
approaches have been used with AID (Activation-Induced Cyti-
dine Deaminase) knockout cells,28 showing that AID accelerates
clonal evolution in BCR-ABLC pB-ALL, or with C/EBPb¡/¡
cells, demonstrating that C/EBPb is involved in BCR-ABL-
mediated myeloid expansion.29
These transduction-based approaches, although very useful in
basic research aimed at understanding the molecular mechanisms
underlying the synergy and leukemogenic effects of ALL collabo-
rating lesions, have the same drawbacks previously mentioned for
viral transduction, and henceforth we will not discuss them in
more detail in the remaining sections.
Another possibility of introducing the second hit, instead of
using a candidate-based approach, comes from the combination
of transgenic lines expressing the “first hit” with some forward
genetics approach in which genetic alterations are induced that
interact with the first oncogenic hit to change some aspect of the
induced disease (e.g., latency, incidence, aggressiveness or other
phenotype). Afterwards, these alterations can be identified and
their relevance for human disease can be evaluated. In the context
of transgenic BCR-ABLp210 mice,30 Miyazaki et al.31
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backcrossed them to BXH2 mice, a recombinant inbred mouse
strain that develop leukemia mainly due to a horizontally trans-
mitted replication-competent retrovirus. Some mice developed
acute lymphoblastic leukemias and this was due to aberrant
expression of the Zfp423 (Zinc finger protein 423, also known as
Early B-cell factor-associated zinc finger protein, Ebfaz) gene, show-
ing that Zfp423 possesses a cooperative oncogenicity with BCR-
ABLp210 in vivo, accelerating disease onset, increasing aggres-
siveness and changing the tumoral phenotype. Zfp423 binds to
and interferes with the activity of Ebf1, a master regulator or B
cell differentiation from the earliest stages, therefore suggesting a
mechanism of action for the cooperative oncogenicity.31 How-
ever, the fact that one has to introduce second cooperating hits
that naturally happen during human pB-ALL development may
imply that the model does not fully mimic human pB-ALL.
The use of inducible systems in which one can control the
timing of the action of the oncogene has enabled a deeper under-
standing of the etiopathogenesis of pB-ALL. For example, induc-
tion of the expression of BCR-ABLp210 under the control of a
tetracycline-controllable promoter led to the development of
lethal acute pre-B cell leukemia in 100% of the mice,32 and the
pathology was reversible upon discontinuation of oncogene
expression. However, it has to be noted that the p210 form of
BCR-ABL is only associated with B-ALLs in humans in the con-
tent of a blast crisis which, conversely, stops responding to
BCR-ABL inhibition by Imatinib. In other study, using the pB-
ALL-associated BCR-ABLp190 form in a tetracycline controllable
system, it has been shown that inactivation of the oncogene
expression, however, does not stop tumor growth once initi-
ated.33 These inducible transgenic mice suffer from pB-ALL that
cannot be rescued by oncogene inactivation or by Imatinib treat-
ment, similarly to what happens in humans, suggesting that the
induction of tumorigenesis does not only depends on the onco-
gene, but also largely on its pattern of expression, and pointing
toward a setting in which the oncogene imposes a leukemic stem
cell-specific epigenetic context in which oncogene inactivation
cannot lead anymore to a reversion of the phenotype.33 The dis-
crepancies between the results arising from models that are not so
dissimilar in their design also highlight and exemplify the impor-
tance of defining stringent phenotypic requirements before con-
cluding that a given mouse model actually recapitulates one of
several aspects of the pathology in humans.
The use of inducible systems allows a tighter control of the
conditions required for the disease to originate or progress, and
permits the testing of the role of other variables in pathogenesis.
One of these variables is aging. Using the aforementioned induc-
ible BCR-ABLp190 transgene, it has recently been shown that
cells from old mice develop leukemias at a much faster rate than
cells from young animals, when transplanted into recipients of
the same age (4 weeks), therefore suggesting that an increase in
the age at which transformation occurs has a direct impact in the
malignant potential of leukemic cells.34
E2A-PBX1C or E2A-HLFC GEMMs
Many of the translocations associated to pB-ALL involve tran-
scription factors whose function becomes deregulated as a result
of the generation of a chimeric protein. For example, the essential
regulator of B cell development E2A is involved in 2 transloca-
tions35,36 which are always associated with pB-ALL in humans.
One of them is the translocation t(1;19)(q23;p13.3) originating
the E2A-PBX1 fusion gene, mainly present in childhood leuke-
mias, but also in adult ones, with very different prognoses, since
E2A-PBX1C childhood pB-ALLs have a favorable outcome, while
adult ones have a much poorer evolution. Many in vitro experi-
ments have shown that E2A-PBX1 is capable of transforming
cells, but the in vivo experiments in mice have yielded inconsis-
tent results. Transgenic expression from an immunoglobulin pro-
moter/enhancer led to the generation of T-lymphoblastic
lymphomas by 5 months of age,37 most likely due to the today
well-known expression of these regulatory elements in T cell
development. However, the numbers of B cells in the bone mar-
row of these mice were reduced by 60% to 80%, therefore sug-
gesting a toxic effect of the oncogene in this compartment. This
model was also the basis to study the role of PBX1 homeodomain
in oncogenesis, and a mutant form of E2A-PBX1 lacking this
domain proved to have similar oncogenic effects compared to the
full-length oncogene.38
The aforementioned E2A-PBX1 transgenic mouse model has
been used in combination with forward genetic analyses to iden-
tify genes that could potentially collaborate in leukemogenesis.
Retroviral insertional mutagenesis using Moloney Murine Leuke-
mia Virus (M-MuLV, MMLV) was employed to identify collab-
orating oncogenes. This approach allowed the identification of
mutations in Pim1 (ref. 39) and Notch1 (ref. 40) as collaborating
in the development of thymic lymphomas.
Other transgenic model, based on similar lymphoid-specific
promoter/enhancer regulatory elements, also developed mainly
T-cell neoplasias and, with less frequency, B-ALLs with a longer
latency.41 To avoid the interference of the T-cell disease and to
enhance the occurrence of B-cell leukemias, these E2A-PBX1
transgenic animals were crossed into a CD3e¡/¡ background,
which lacks T cells. The resulting animals were subjected to ret-
roviral insertional mutagenesis using MMLV to reveal collaborat-
ing genes. The identification of relevant targets showed that the
Hoxa gene cluster is preferentially targeted in the E2A–PBX1-
induced tumors, therefore pointing toward a functional collabo-
ration between these oncogenes in pB-ALL.41 Further studies
crossing E2A-PBX1 transgenic mice with specific transgenes
expressing genes from the Hoxa cluster showed oncogene collabo-
ration also in T cell leukemias,42 although this oncogene has not
ever been found to be associated with T-ALL in humans.
Also involving the E2A gene, the E2A-HLF fusion protein
arises as a result of the translocation t(17;19)(q22; p13.3) and,
although it is present with a very low frequency in general, its
prognosis is highly unfavorable. Transgenic models in which the
E2A-HLF expression is driven by the immunoglobulin enhancer
resulted in interference with the differentiation of the lymphoid
lineages, causing T-cell apoptosis, B-cell maturation arrest, and
development of long-latency T-ALLs. Tumors were monoclonal,
suggesting the need for secondary genetic events, and presented
the phenotype of developmentally blocked T cells or, infre-
quently, B-cell progenitors.43,44 These results and those from the
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E2A-PBX1 mice have been interpreted as due to a dominant-neg-
ative effect of the E2A fusion proteins with the normal dimeriza-
tion dynamics of the endogenous E2A proteins and Id proteins,
required for normal lymphocyte differentiation.45
Since the previously mentioned methods of ectopic expression
did not fully recapitulate the human pathology related to
E2A-HLF, more sophisticated approaches have been undertaken.
A conditional knock-in model was generated in which the E2A-
HLF cDNA was placed into the E2a locus, mimicking the
human situation.46 The expression of the oncogene was blocked
by a Neo cassete flanked by loxP sites, so that it could be activated
by using (in this case) the interferon-inducible Mx-Cre transgenic
line.47 However, no disease was developed in the mice during a
long observation period, therefore indicating either the need
for secondary alterations which naturally do not occur in
mice, or that the way these leukemias are initiated in humans
follows a different pattern that the one used to model the dis-
ease in mice. To provide for the secondary hits, retroviral
insertional mutagenesis was used, which resulted in the induc-
tion of acute leukemias, some of them of the B cell type, that
also presented with features like the previously described coa-
gulopathic property of translocation t(17;19)-positive leukemic
cells.47 Investigation of the retrovirally overexpressed genes
involved in this process led to the identification of several
genes, among them Gfi1, Ikaros and zinc-finger protein 521
(Zfp521), which was afterwards found to be also overexpressed
in human leukemic E2A-HLFC cell lines. Zfp521 is homolo-
gous to the previously mentioned Zfp423 gene, and can also
interfere with the activity of the master regulator or B cell dif-
ferentiation Ebf1, therefore suggesting a mechanism of action
for the cooperative oncogenicity.
TEL-AML1C GEMMs
The translocation t(12;21)(p13;q22) (TEL-AML1, RUNX1-
ETV6) accounts by itself for 25% of the cases of childhood pB-
ALL, and it is specifically linked to pB-ALL in humans. Andreas-
son et al. expressed the TEL-AML1 fusion gene under the control
of the immunoglobulin heavy chain enhancer/promoter, but
these mice did not develop any hematologic disorder of any
kind.48 There is no follow-up of this mouse model in the litera-
ture, but a very similar transgenic strategy has been used
recently,49 showing again a very mild phenotype, with only a
minor increase in early B cell progenitor percentages and lacking
any malignant phenotype. A recently generated CD19-TEL-
AML1 BAC-transgenic mouse does not have any detectable hae-
matopoietic anomaly, although ROS levels in B cells are elevated,
therefore suggesting that the expression of the oncogene might
trigger mutagenesis through the enhanced production of reactive
oxygen species (ROS).50
In one of the latest studies,51 a knock-in was generated in such
a way that a copy of the AML1 gene was introduced in a condi-
tional manner into the endogenous Tel locus of the mouse. Using
this model, Schindler et al. could show that TEL-AML1 can
induce a limited expansion of HSCs. However, once again, these
mice did not develop pB-ALL and, only with the additional treat-
ment of the mice with the powerful mutagen ENU, they develop
T cell malignancies, which is in sharp contrast to what can be
seen in human patients.51 A similar knock-in approach has
been recently employed by van der Weyden et al.52 They
introduced, in a constitutive manner, the AML1 cDNA into
the mouse Tel locus, but they also introduced downstream of
it an Internal Ribosomal Entry Site (IRES) followed by the
cDNA of a hyperactive variant of the Sleeping Beauty transpo-
sase. In order to model the second hit believed to occur in
human pB-ALL patients, they crossed these mice with mice
carrying the T2Onc transposon array.53 These mice are, so far,
the only TEL-AML1 model that has been reported to generate
(albeit with a low frequency, 13 out of 90) pB-ALL.52 In this
study, several of the genes or the chromosomal locations
altered by the transposase activity in the pB-ALLs arising in
the mice were coincident with genes known to be involved in
human pB-ALLs, therefore showing the validity of this kind of
approaches. However, these mice also present with other leu-
kemias, with even higher frequencies (AML, 34 out of 90
mice; and T-ALL, 21 out of 90) which, again, do not recapitu-
late the high specificity of TEL-AML1 for CD10C, CD19C
human leukemias.
Once more, the lack of accuracy in recapitulating the human
disease shows that there are aspects of the leukemia biology that
are still being overlooked when attempting to model the disease
in mice. In the case of human patients, it was described more
than 10 y ago that the frequency of newborns carrying the TEL-
AML1 translocation in their blood is higher than the overall inci-
dence rate of pB-ALL.54 This finding, although it remains con-
troversial 55-58 would imply that preleukemic clones are frequent,
but they are normally controlled or eliminated by natural pro-
cesses, and only a percentage of them finally give rise to an overt
leukemia. In this context, one would also expect that the pene-
trance of pB-ALL in TEL-AML1C GEMMs should be very low,
even if one could exactly mimic target cell, oncogene levels, etc.,
like they occur in humans (which is most likely not the case, as
we are seeing). From this point of view, the TEL-AML1 translo-
cation (and possibly other pB-ALL-related ones) could be almost
considered like an increased susceptibility allele with a moderate
final influence in the appearance of the disease. Accepting this,
the nature and incidence of the second hit(s) (either endogenous
or due to the exposure to environmental factors) becomes the
essential leukemia-unleashing event.59,60 There are many possible
candidate alterations that could play a role, but their cause is still
to be determined: exogenous or endogenous exposures, genetic
susceptibility, and chance can all have a role.61 Still, an appropri-
ate first-hit TEL-AML1 animal model is missing and it will be of
essential importance to test for all the possible contributing sec-
ondary causes, but the nature of the disease, as discussed, makes
it difficult to exclude potential contributing causes on basis of
negative results from animal models. In general, in light of these
recent discoveries, a common problem of all the mouse models
discussed in this review is that the design of the models considers
that the oncogene is expressed in all B-cells since the beginning, a
situation that does not happen in humans, where the preleukemic
clone can reside within the BM HSCs without peripheral contri-
bution for years.
2840 Volume 13 Issue 18Cell Cycle
MLL-involving translocations-based GEMMs
Among pediatric ALLs, a special case is that of infant leuke-
mias associated with translocations involving the MLL gene.
They occur typically in the first year of age, and they have a very
bad prognosis. The rearrangements have been shown to take
place in utero. More than 50 different translocations have been
identified in which MLL is involved, and the most frequent ones
in pB-ALL (80% of the cases in which the MLL gene is involved
in pB-ALLs) are those affecting the genes AF4, AF9, ENL, AF10
and AF6 (ref. 62). Contrary to what we have described until
now, in MLL-related ALLs, additional genetic alterations are
uncommon (although alterations in FLT3 expression are fre-
quently seen in MLL-based leukemias63), suggesting that all the
changes necessary for leukemogenesis are directly or indirectly
driven by the oncogene. This could be due to the particular
nature of MLL as a methyltransferase involved in the regulation
of Hox genes, and in establishing histone methylation patterns
that regulate gene expression.64
Knock-in mice chimeras carrying ES cells in which the AF9
cDNA was introduced into the mouseMll locus developed leuke-
mias (mainly AML, but also B-ALL), but the long latency seems
to support the need for additional genetic hits in this model.65,66
Using this model, the different kinetics of leukemia generation
from fetal liver (FL) or bone marrow (BM) cells was studied,
showing that there is a significant delay in the onset on leukemia
from transplanted transgenic FL cells when compared with BM
cells, suggesting that, by the time the cells have matured to the
BM stem/progenitor stage, secondary hit(s) have already taken
place.67
From a mechanistic point of view, one of the most sophisti-
cated and elegant mouse models of chromosomal translocations
generated so far involved the induction of such translocations
between the endogenous Mll and AF9 loci of the mice in vivo.68
This same approach was afterwards applied to mimic in the
mouse the translocation t(11;19)(q23;p13.3) involving the Mll
and Enl loci.69 LoxP sites were introduced in the respective loci
in chromosomes 9 and 17 (Mll and Enl chromosomes, respec-
tively), and recombination was achieved by using the pan-haema-
topoietic Lmo2-Cre recombinase.70 These mice developed a
“myeloproliferative-disease-like myeloid leukemia” in less than
6-months’ time, therefore directly implicating Mll-Enl in leuke-
mic development. More closely concerning human pediatric pB-
ALLs, a constitutive mouse model carrying a knock-in of AF4
into the Mll locus developed mixed lymphoid and myeloid
hyperplasias and B-cell lymphomas, with a long latency.71 Also
in this article, MLL-AF9 knock-ins were generated (same ones as
described above) that developed myeloid malignancies.
Another experimental and very innovative approach led to the
generation of conditional Mll-AF4 mice by using the so-called
“invertor” technology, in which the AF4 cassette was knocked-in
into theMll locus in an inverted orientation and flanked by lox-P
sites. The action of the Cre led to the inversion of the cassette
and the subsequent generation of the chimeric Mll-AF4 onco-
gene.72 Using different, lymphoid specific, Cre recombinases,
these mice developed B cell neoplasias of a mature phenotype
(diffuse large B cell lymphomas), instead of the pro-B-ALLs
usually associated withMLL-AF4C infant leukemia. It is reported
that constitutive expression of the fusion oncogene is embryonic
lethal. However, one aspect that is clear from all these models is
that, even if the knock-in expresses the oncogene all throughout
the organism, only haematopoietic malignancies develop in the
mice, indicating that the MLL fusions are only tumorigenic in
this compartment. The authors conclude that, according to these
data, Mll-AF4 is oncogenic in committed cells of the lymphoid
lineage and does not have to be expressed from the HSCs. How-
ever, one important question that remains is what the phenotype
would be if the expression of the Cre had been targeted to more
primitive compartments.72 Another model of infant MLL-AF4-
associated human pro-B-ALLs was developed by Krivtsov et al.73
using, interestingly, a similar strategy but a different Cre-line.
They used a conditional knock-in model of AF4 into the mouse
Mll locus, preceded by a loxP-flanked STOP cassette, in combi-
nation with an interferon-inducible, pan-haematopoietic Mx1-
Cre line.47 Fourteen out of 22 mice developed a disease consis-
tent with acute leukemia, and unsupervised hierarchical cluster-
ing analysis of microarray profiling demonstrated that these
ALLs were similar to pre-B cells. Furthermore, recent studies sug-
gest that MLL fusion proteins control gene expression by recruit-
ing the histone H3 lysine79 (H3K79) methyltransferase
DOT1L74,75 and, comparing leukemia cells from the Mll-AF4C
mice with human ones, it has been shown73 that H3K79 methyl-
ation is similarly enhanced at many loci, and this elevation is cor-
related with enhanced gene expression. Also, suppression of
H3K79 methylation leads to inhibition of gene expression in
MLL-AF4C cells, therefore suggesting that inhibition of DOT1L
may be a therapeutic possibility in this type of ALLs.76
This aforementioned mouse model is a good example of how
the combination of an accurate molecular copy of the genetic
lesion taking place in humans, together with its activation in the
right cellular compartment, can lead to a much improved model
of human leukemia. This question of what is the right target cell
for the action of the oncogene (which we will discuss in a more
general way at the end) is well illustrated with other examples,
also concerning mouse models of MLL-associated translocations.
Although some of these models are based on retroviral transduc-
tion, we will discuss some of the findings obtained in this particu-
lar context. Using retroviral transduction ofMLL-ENL in defined
mouse haematopoietic subpopulations, it was found that the
oncogene could induce the leukemic phenotype in both self-
renewing stem cells and short-lived myeloid progenitors.77 Also,
it has been described that retrovirally transduced MLL-AF9 can
transform both early haematopoietic progenitors78 and commit-
ted myeloid progenitors.79 However, when studying the role of
Mll-AF9 in knock-in mice, it was found that there are high
expression levels of the oncogene and its downstream target genes
in HSCs compared to committed progenitor cells.80 This has
direct consequences in the leukemogenic capacity, since there
seems to be a direct relationship between oncogene dosage and
the cellular susceptibility to transformation in committed pro-
genitor cells, which can be transformed by retroviral-driven onco-
gene but not by the endogenously controlled one.80 Using a
conditional transgenic model of MLL-ENL, it has recently been
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shown thatMLL-ENL, when expressed at a level similar to that of
the endogenous Mll locus, can selectively induce the leukemic
transformation of a restricted subpopulation of HSCs, and that
this effect is achieved through the upregulation of the Promyelo-
cytic leukemia zinc finger (Plzf ) gene.81 Something similar had
been shown before for Evi1 (ref. 82) and also, importantly in the
case of MLL fusion genes, for Hox genes like Hoxa9 (ref. 83).
These findings highlight the importance that expression levels
and windows might have in the generation of a reliable model
that faithfully recapitulates human disease. Finally, it has also
been shown, using Mll-AF9 knock-in mice, that there is a step-
wise progression in the pathogenesis of the ALL, from prenatal to
postnatal stages, in such a way that there are significant differen-
ces between prenatal and postnatal myeloid cells, and suggesting
that there are several steps that precede the development of overt
leukemia in the adult mouse.84
Loss-of-function-based pB-ALL GEMMs
We have revised the most representative genetic alterations
classically associated with pB-ALL. However, there are others
that, although accounting only for a small number of cases, are
of biological relevance because of the mechanistic information
that they provide us regarding the biology of leukemia. On the
other hand, many of them have not yet been modeled in geneti-
cally engineered mice, and only, if at all, in retroviral transduc-
tion settings.
The B cell master regulator PAX5 is frequently inactivated by
mutation in pB-ALLs,85 and it is also involved in translocations
fusing it to TEL, FOXP1, ZFP512 or to ELN.86 Although it is
presumed that the chimeric proteins resulting from these translo-
cations involving PAX5 act as dominant-negative forms, interfer-
ing with the normal B-cell developmental program,87 the truth is
that, as of today, there are not GEMMs available to study in
detail their role in vivo. A conditional loss-of-function model of
Pax5 has shown that its loss in committed B cells in vivo leads to
the development of tumors with the properties of progenitor cell
lymphomas, with a gene expression pattern similar to that of
uncommitted Pax5¡/¡ pro-B cells, although they carry immuno-
globulin heavy-chain and light chain gene rearrangements, indi-
cating that they must originate by dedifferentiation from
immature or mature B cells.88 Also, new studies demonstrate that
germline hypomorphic mutations of PAX5 are associated with
susceptibility to pB-ALL, implicating PAX5 mutations in familial
leukemia predisposition syndromes.89,90 The combination of het-
erozygous or homozygous (conditional) loss-of-function alleles of
Pax5 with gain-of-function translocation models will likely lead
to acceleration or an increased penetrance of the disease.
This effect has already been detected in the context of muta-
tions in the Ikaros (Ikfz1) gene, as we have previously mentioned
in the context of BCR-ABL translocation models.24 The IKAROS
mutations that can be found in human patients cover the range
from haploinsuficiency to null mutations, including mutations
with a dominant negative effect (due to the dimerization required
by IKAROS and its related proteins AIOLOS, HELIOS or
EOS),91 and they are not randomly distributed among the differ-
ent ALLs, suggesting, for example, that the selective pressure
necessary for the acquisition of strong IKAROS mutations is
higher in BCR-ABLC positive pB-ALLs. IKAROS mutations are
in the majority of the cases second hits,20 but also specific inher-
ited polymorphisms of IKZF1 predispose to pB-ALL (reviewed
in ref. 91). The roles of Ikaros in lymphoid development are
manifold, so modulations of its activity by mutations or among
different allelic variants will most probably have different impacts
in leukemic development and progression. This also makes it dif-
ficult to choose a specific lack-of-function Ikaros general mouse
model that could be of general applicability for the study of its
role in ALLs.
Similarly to the 2 examples that we have described, there are
many other genes that have been found to be associated with pB-
ALL in humans with a small frequency (individually), either as
first or second hits. In general, the interference with genes
involved in B cell development or function is related with altera-
tions in B cell differentiation and hence, is susceptible to partici-
pate in leukemic evolution. Along these lines, genes involved are
EBF1, RAG1 and RAG2 genes, signal transduction genes like
JAK/STAT or SLP65/BLNK, cytokine receptor genes like IL7R,
FLT3, TSLP/CRLF2. Also of course, like in most other cancers,
genes involved in cell proliferation/cell cycle like CDKN2A/
CDKN2B, RB1, TP53, or in control of cell death like BCL2, or
BTG1, are also participating in many cases of human B-ALL
(reviewed in 61,92,93).
Loss-of-function mouse models affecting these genes and
related ones exist, for the majority of them. Many of them pres-
ent with characteristics resembling, in a variable degree, human
ALLs. For example, indirect interference with the function of
Ebf1 leads to the development of ALLs in a mouse model of ret-
rovirally-induced mutagenesis.94 Rag1 deficiency contributes to
leukemogenesis in mouse when it is combined with secondary
oncogene activation, like p53 (ref. 95) or tumor suppressor gene
inactivation, like p19ARF96. The combined lack of Rag1 and
p19Arf gives rise to leukemias characterized by the appearance of
a new subset of Sca1CCD19C B-cell-precursor cells containing
leukemia-initiating cells, characterized by increased expression of
Notch1. Using Stat5fl/fl Mx1Cre mice, it has been shown that the
STAT5 signaling pathway is required for the maintenance of the
leukemic state in BCR-ABLC leukemias.97 It has also been shown
that haploinsufficiency of either Pax5 or Ebf1 synergized with a
constitutively active form of Stat5b to rapidly induce ALL in
100% of the mice.98 Also, in AML mouse models it has been
demonstrated that Jak inhibitors suppress the leukemic pheno-
type.99 Slp65¡/¡ mice spontaneously develop pre-B cell leuke-
mia, whose proliferation is believed to be driven by constitutive
Jak3/Stat5 signaling.100
Chromosomal rearrangements affecting cytokine receptors are
becoming a subclass in themselves, especially the ones affecting
TSLP/CRLF2, leading to its increased expression, very often asso-
ciated with mutations activating JAK1 or JAK2. Not suitable
mouse models are yet available to try and reproduce in the mice
their effect in human B-ALL biology. The role of FLT3 deregula-
tion in MLL-leukemias is well-ascertained, and it has been shown
in a retrovirally transduced mouse model that Flt3 inhibition
might be of therapeutic value in this type of leukemias.63
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Many GEMMs exist already for both the loss- and gain-of-
function of genes involved in the control of cell proliferation, cell
cycle, apoptosis, etc. Therefore, the individual contributions of
each of these genes to leukemia can be evaluated, either alone or
in combination with other models, in a relatively simpler way
using the already existing models.
Finally, it is also important to mention that there are no good
models available of high hyperdiploid pB-ALL, because the
modeling of leukemias characterized by the gain of many whole
chromosomes is technically very difficult with today’s tools.
However, such models would be highly desirable as this genetic
subgroup is very frequent, exceeding even that of TEL-AML1C
pB-ALL in children.
Conclusions and future directions
The GEMMs of pB-ALL generated so far have provided an
enormous amount of extremely valuable biological information,
have helped to demonstrate the oncogenic nature of the different
genetic lesions present in human patients and have provided the
ground for the development of new targeted therapies. However,
in scientific research, there is always a constant evolution and
incorporation of new concepts. The most recent findings in the
field of leukemia and in cancer in general, are revealing the exis-
tence of complex intratumoral heterogeneity, intricate internal
clonal progression, hierarchical, stem cell-based, structure of the
leukemic population and novel roles of oncogene function
beyond the deregulation of cellular proliferation and survival.
101-103 All these aspects must be now taken into account in our
attempts to generate suitable animal models of leukemia that can
faithfully recapitulate these characteristics of the disease in
humans (Fig. 1).
The main focus while attempting to model cancer has been
put in the oncogene, while the aspect of the cellular context in
which the oncogene is exerting its action was generally taken for
granted, since it was normally assumed that the cancer cell-of-ori-
gin correlated with the closest non-pathological relative of the
main cellular type composing the mass of human tumors. How-
ever, from the restricted capacity of the existing GEMMs to accu-
rately model all the aspects of the human disease, it is clear that
this aspect needs to be incorporated in the generation of new
mouse models (Fig. 1C and D). Only when acting in the right
type of cell can the oncogene originate the right leukemic pathol-
ogy. This cell-of-origin usually does not have to present any
phenotypic similarity with the cells forming the main tumoral
mass.103 One clear example can be found in chronic myeloge-
nous leukemia, in which the translocation creating the
BCRABLp210 oncogene appears and exerts its first oncogenic
effects in HSCs, in spite of the fact that the disease is character-
ized by the accumulation of differentiated granulocytic cells.104
An additional aspect is that the initiating genetic lesion(s) found
in human leukemias seems to take place only during certain spe-
cific periods, and to be restricted to a limited number of cells
because they can reprogram the right target cell into a specific
tumoral cell fate,103,105,106 implying that oncogenes do not have
a homogeneous mode of action all throughout the tumoral cell
population, and at all the stages of cancer development.
From all these evidences we can conclude that mouse models
in which the initiating oncogenic alteration(s) is not directed to
the right cell-of-origin are unlikely to accurately recapitulate the
etiology of the human disease, and will originate an inaccurate
model of human leukemia (Fig. 1C, D). However, even targeting
the oncogene expression to the stem/progenitor compartment is
still not completely analogous to what happens in humans, since
in humans the preleukemic clone carrying the translocation is
restricted to the BM during the preclinical stage. This is however,
not the case in most currently existing mouse models, in which
the transgenic lesion, once activated, is transmitted (and, in the
majority of the cases, expressed) to all the descendants of the tar-
geted cell during the preclinical phase. Therefore, an essential
need is to limit oncogene expression to the right developmental
compartment, avoiding “off-target” windows of expression, both
before and after the right moment in which these lesions appear
and cause the leukemogenic effects in humans. Ideally, initially
one could think of knock-in approaches as the ones having the
major chances or recapitulating the correct pattern of oncogene
expression. However, this could also cause undesirable variations
in the levels of expression between the different developmental
compartments that, in turn, lead to differences in the leukemo-
genic capacity, since the relationship between oncogene dosage
and cellular susceptibility to transformation is different between
progenitors and HSCs.80 So, although it might seem counterin-
tuitive, it could happen that the right pattern of expression might
in some cases be better provided by other promoters, rather than
by the endogenous mouse regulatory sequences. Once more, the
search for these regulatory elements must be largely empirical,
but will undoubtedly be profitable.
In summary, pB-ALL is the subject of intense research around
the world, and the different GEMMs generated so far have been
extremely useful to better understand many aspects of leukemic
development. However, many questions about the etiology of
the human disease remain unanswered. How exactly does
pB-ALL start and how does it evolve? Mouse models of pB-ALL
in which precise control of the timing of the oncogene action is
possible will be instrumental to address these and other questions
to understand the complexity of pB-ALL in order to know how
to eradicate the preleukemic clone and/or to inactivate its conver-
sion into a full malignant leukemia. Similarly, assessing the abil-
ity of any candidate therapy to destroy these cells would be
crucial to predict its efficacy. Here again the right mouse models
will be pivotal tools to achieve this aim.
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